



**Figure S2.** Inhibition of Cdk5 with roscovitine alleviates GC-mediated bone loss by reducing osteoclastogenesis. Static and dynamic bone histomorphometry was performed from different treatments and following parameters were calculated from cortical bone: **(A)**, osteoblast surface per bone surface – Ob.S/BS (%); **(B)**, osteoblast number per bone parameter – Ob.N/B.Pm (mm<sup>-1</sup>); **(C)**, representative images of dual calcein labeling (green) (scale: 50 μm); **(D)**, mineral apposition rate - MAR (μm/day); **(E)**, bone formation rate - BFR/BS (μm<sup>3</sup>/μm<sup>2</sup>/day); **(F)**, osteoclast surface per bone surface – Oc.S/BS (%); **(G)**, osteoclast number per bone parameter – Oc.N/B.Pm (mm<sup>-1</sup>) (n=4-6). Data are represented as box and whisker plots with min. to max. as well as superimposing all of the data points. Statistical differences between two groups were determined by one-way ANOVA and Tukey's test. \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.